A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy

A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African RG7800 chemical information Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered threat Later age of onset No risk association No threat association No threat association Decreased risk of eR+ BC No risk association enhanced overall danger No danger association increased risk of eR- BC Chaetocin price improved risk elevated risk No danger association enhanced risk No threat association increased threat No risk association enhanced danger No risk association elevated danger No risk association Decreased danger No threat association increased overall danger No danger association No threat association enhanced general danger No risk association Decreased risk of eR+ BC improved threat of eR- BC No danger association Decreased risk No risk association increased risk of eR+ No risk association No threat association Decreased threat of eR- BC Decreased risk of eR+ BC No danger association Decreased threat of eR+ No threat association No risk association increased overall threat Decreased general threat No danger association No danger association increased threat of eR- BC elevated risk increased risk elevated risk increased threat in eR+ earlier age of onset enhanced danger (A allele) earlier age of onset (C allele) Decreased danger Decreased threat elevated threat Decreased survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 3 UTR HPGD 3 UTR IGF-1R 3 UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation improved frequency in BRCA1 carriers/no threat association improved threat of TNBC Decreased risk increased danger and poor survival earlier age of onset improved threat elevated threat Decreased danger Decreased all round danger No danger association Decreased threat of eR+ BC No risk association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable two (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Decreased danger Later age of onset No risk association No danger association No danger association Decreased risk of eR+ BC No danger association enhanced overall threat No risk association elevated danger of eR- BC enhanced threat increased danger No risk association enhanced risk No danger association enhanced risk No risk association enhanced danger No threat association improved threat No threat association Decreased danger No danger association elevated overall risk No risk association No danger association improved all round danger No risk association Decreased danger of eR+ BC increased threat of eR- BC No danger association Decreased danger No risk association improved danger of eR+ No threat association No risk association Decreased danger of eR- BC Decreased threat of eR+ BC No danger association Decreased risk of eR+ No threat association No risk association increased all round danger Decreased all round danger No danger association No risk association improved threat of eR- BC improved threat enhanced danger enhanced risk increased risk in eR+ earlier age of onset increased danger (A allele) earlier age of onset (C allele) Decreased threat Decreased risk increased risk Decreased survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 3 UTR HPGD three UTR IGF-1R 3 UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no threat association increased danger of TNBC Decreased threat enhanced danger and poor survival earlier age of onset improved danger enhanced risk Decreased risk Decreased all round danger No threat association Decreased danger of eR+ BC No risk association increas.

Leave a Reply